Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Anticancer carrier-linked prodrugs in clinical trials.
Kratz F, Abu Ajaj K, Warnecke A. Kratz F, et al. Expert Opin Investig Drugs. 2007 Jul;16(7):1037-58. doi: 10.1517/13543784.16.7.1037. Expert Opin Investig Drugs. 2007. PMID: 17594188 Review.
Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix.
Hochdörffer K, Abu Ajaj K, Schäfer-Obodozie C, Kratz F. Hochdörffer K, et al. Among authors: abu ajaj k. J Med Chem. 2012 Sep 13;55(17):7502-15. doi: 10.1021/jm300493m. Epub 2012 Aug 27. J Med Chem. 2012. PMID: 22882004
Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K, Graeser R, Kratz F. Abu Ajaj K, et al. Breast Cancer Res Treat. 2012 Jul;134(1):117-29. doi: 10.1007/s10549-011-1937-9. Epub 2012 Jan 8. Breast Cancer Res Treat. 2012. PMID: 22228402
Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative.
Abu Ajaj K, El-Abadla N, Welker P, Azab S, Zeisig R, Fichtner I, Kratz F. Abu Ajaj K, et al. Eur J Cancer. 2012 Sep;48(13):2054-65. doi: 10.1016/j.ejca.2011.08.003. Epub 2011 Sep 19. Eur J Cancer. 2012. PMID: 21937219
Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
Elsadek B, Graeser R, Esser N, Schäfer-Obodozie C, Abu Ajaj K, Unger C, Warnecke A, Saleem T, El-Melegy N, Madkor H, Kratz F. Elsadek B, et al. Among authors: abu ajaj k. Eur J Cancer. 2010 Dec;46(18):3434-44. doi: 10.1016/j.ejca.2010.08.018. Eur J Cancer. 2010. PMID: 20933385
Development of dual-acting prodrugs for circumventing multidrug resistance.
Abu Ajaj K, Kratz F. Abu Ajaj K, et al. Bioorg Med Chem Lett. 2009 Feb 1;19(3):995-1000. doi: 10.1016/j.bmcl.2008.11.063. Epub 2008 Nov 24. Bioorg Med Chem Lett. 2009. PMID: 19131246
In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
Elsadek B, Graeser R, Esser N, Schäfer-Obodozie C, Tsurumi C, Abu Ajaj K, Warnecke A, Unger C, Saleem T, Kratz F. Elsadek B, et al. Among authors: abu ajaj k. Prostate Cancer Prostatic Dis. 2011 Mar;14(1):14-21. doi: 10.1038/pcan.2010.43. Epub 2010 Nov 2. Prostate Cancer Prostatic Dis. 2011. PMID: 21042336
Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors.
Daum S, Magnusson JP, Pes L, Garcia Fernandez J, Chercheja S, Medda F, Nollmann FI, Koester SD, Perez Galan P, Warnecke A, Abu Ajaj K, Kratz F. Daum S, et al. Among authors: abu ajaj k. Nucl Med Mol Imaging. 2019 Jun;53(3):189-198. doi: 10.1007/s13139-019-00587-w. Epub 2019 Feb 20. Nucl Med Mol Imaging. 2019. PMID: 31231439 Free PMC article.
13 results
Jump to page
Feedback